MSICS Pharma Secures $3.6 Million to Expand Psychedelic Drug Trials
Israeli biotech MSICS Pharma secured $3.6 million to expand its clinical trials for psilocybin treatments targeting depression and OCD.
Fusion VC
Navigation
Israeli biotech MSICS Pharma secured $3.6 million to expand its clinical trials for psilocybin treatments targeting depression and OCD.